China Stone Medicine Group's Coronary Virus MRNA vaccine SYS6006 is included in emergency use in China, which is also the first mRNA vaccine approved by China for emergency use.
According to the interface news report, the Stone Medicine Group announced on Wednesday (March 22) in the Hong Kong Stock Exchange on Wednesday (March 22).Disease MRNA vaccine (SYS6006) is incorporated into emergency use in China to prevent disease caused by infection caused by new coronary virus (SARS-COV-2) infection.
Announcement saying that the group will fully consider the current characteristics of coronary virus mutation, predict the trend of mutation in the future, promote the research and development of the iterative crown disease MRNA vaccine for new mutant plants, and actively promote other on the platform other on the platformProduct development process.
According to previous statistics, 13 domestic vaccines have been approved in China, and it has covered an activated vaccine, restructuring protein vaccine, and virus carrier vaccine.
China has not approved any imported mRNA vaccine so far.The MRNA vaccine developed by the Chinese Medicine Group for the mutation of Omikon was approved by the National Drug Administration's clinical trial on January 19 this year.
The first messenger ribonucleic acid (MRNA) coronary vaccine developed by Chinese Pharmaceuticals Kangxino Biological Co., Ltd. also entered the trial production stage in January this year.
